N/A N=162 Tumor: Breast Ratio Study
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
N/A N=60 The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease
Breast Abnormalities
Primary: Specificity of MBI. Specificity is Defined as the Number of True Negatives/ Total Number of Negative Pathology Results. — 27 lesions
Phase 2 N=257 Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
Breast Cancer
Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants
N/A N=36,444 Surveillance Imaging Modalities for Breast Cancer Assessment
Breast Cancer
Primary: Number of Breast Cancers Detected — 279; 27 cancers detected
Phase 2 N=12 Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
Breast Cancer · Ductal Carcinoma in Situ - Category
Primary: 18F-FES Uptake in DCIS — 1.43 SUV
Phase 3 N=163 Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
N/A N=20 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®
Breast Cancer · Ductal Carcinoma in Situ
Primary: Ipsilateral Recurrence Rate — 0 participants
Phase 2 N=69 Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
Breast Cancer
Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort
Phase 2 N=234 Intraoperative Detection of Residual Cancer in Breast Cancer
Breast Cancer
Primary: Collect Data to Refine and Verify the Tumor Detection Algorithm. — 11.3 Percentage
N/A N=20 Tactile Breast Imaging Sensor for Tumor Malignancy Characterization
Breast Cancer
Primary: Size Error in Millimeters — 0 milimeters
Phase 2 N=124 Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
N/A N=45 ARFI, VisR and DDAI Ultrasound for Improving Discrimination of Malignant and Unresponsive Breast Cancer
Breast Cancer
Primary: Correlation of Peak Displacement (PD) for Detecting Malignancy — 4.5803; 8.628 microns — p=0.2988
N/A N=8 Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms
Breast Cancer
Primary: Assess the Ability of the HD PET/CT to Predict Final Histopathologic NAC Response.
Phase 2 N=270 Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Breast Cancer
Primary: Local Recurrence — 3.1 percentage of participants
N/A N=1,007 Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer
Breast Cancer · Contralateral Breast Cancer
Primary: MRI Diagnostic Yield of Cancers in the Contralateral Breast — 30; 114; 3; 822 Participants
Phase 2 N=43 Neoadjuvant Treatment of Breast Cancer
Breast Cancer
Primary: Overall Clinical Response to the Dose Dense Regimen — 43 Participants
N/A N=97 Study of Prone Accelerated Breast And Nodal IMRT
Lymphedema
Primary: Number of Participants With Acute Toxicity > Grade 2 (Skin Toxicity Grade 3 or Above) Occurring Within 60 Days After First Day of Treatment — 4 Participants
N/A N=89 Comparison of MRI and Molecular Breast Imaging in Breast Diagnostic Evaluation
Breast Cancer
Primary: Sensitivity on the Per Patient Level — 25; 27 participants
Phase 2 N=24 SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
Breastcancer · Breast Neoplasm
Primary: Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety] — 24; 11; 8; 7 Participants
N/A N=2,978 Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue
Breast Carcinoma
Primary: Rate of Detection of Invasive Cancers — 9; 14 Participants
N/A N=31 Improved Breast MRI With SWIFT
Breast Cancer
Primary: Lesions — 0; 12 lesions
Phase 2 N=111 A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Breast Cancer
Primary: Overall Response Rate (ORR) — 40.7; 5.0; 8.8 percentage
Phase 2 N=76 Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Breast Cancer · Chest Wall Disease
Primary: Disease Control Rate (DCR) at 18 Weeks — 20; 17 percentage of participants
Phase 2 N=37 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Phase 2 N=60 Feasibility Study of Intraoperative Imaging in Breast Cancer
Breast Cancer
Primary: (Phase A Only) Selection of Dose of LUM015 to be Used in Future Breast Trials — 2.1; 4.7; 4.2 Ratio
N/A N=159 A Study to Evaluate the Use of Supine MRI Images in Breast Conserving Surgery
Breast Cancer
Primary: The Mean Distance Between the Image-defined and Palpation-defined Edges of the Tumor. — 7.2 mm
Phase 2 N=217 Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
Breast Neoplasms
Primary: Progression-Free Survival (PFS) — 2.0; 2.7; 1.7; 2.5 Months — p=0.8885
Phase 1 N=82 Effect of Denosumab on Cellular Biomarkers in the Human Breast
Healthy Volunteer, Female, Breast
Primary: Log Ratio of Post-baseline to Baseline Ki-67 Index in Mammary Epithelial Cells — 0.084; -0.100; -0.081 log ratio — p=0.2966
Phase 2 N=40 Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Breast Cancer
Primary: Complete Response Rate — 2; 8 Participants